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Background: Within the UK, during September, there is a pronounced increase in the number of unscheduled
medical contacts by school-aged children (4–16 years) with asthma. It is thought that that this might be caused by
the return back to school after the summer holidays, suddenly mixing with other children again and picking up
viruses which could affect their asthma. There is also a drop in the number of prescriptions administered in August.
It is possible therefore that children might not be taking their medication as they should during the summer
contributing to them becoming ill when they return to school.
It is hoped that a simple intervention from the GP to parents of children with asthma at the start of the summer
holiday period, highlighting the importance of maintaining asthma medication can help prevent increased asthma
exacerbation, and unscheduled NHS appointments, following return to school in September.
Methods/design: PLEASANT is a cluster randomised trial. A total of 140 General Practices (GPs) will be recruited
into the trial; 70 GPs randomised to the intervention and 70 control practices of “usual care”. An average practice is
expected to have approximately 100 children (aged 4–16 with a diagnosis of asthma) hence observational data will
be collected on around 14000 children over a 24-month period. The Clinical Practice Research Datalink will collect
all data required for the study which includes diagnostic, prescription and referral data.
Discussion: The trial will assess whether the intervention can reduce exacerbation of asthma and unscheduled
medical contacts in school-aged children associated with the return to school after the summer holidays. It has the
potential to benefit the health and quality of life of children with asthma while also improving the effectiveness of
NHS services by reducing NHS use in one of the busiest months of the year.
An exploratory health economic analysis will gauge any cost saving associated with the intervention and
subsequent impacts on quality of life. If results for the intervention are positive it is hoped that this could be
adopted as part of routine care management of childhood asthma in general practice.
Trial registration: Current controlled trials: ISRCTN03000938 (assigned 19/10/12) http://www.controlled-trials.com/
ISRCTN03000938/.
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Asthma exacerbations and deaths are known to be sea-
sonal [1]. A number of reports have shown peaks in
asthma exacerbation in school aged children with
asthma associated with the return to school following
the summer vacation [2-10]. These studies mainly report
hospital admissions, although one study has reported
peaks both in hospital admissions and all medical con-
tacts [10].
Children returning to school are exposed to a variety
of novel respiratory challenges including allergens and
viruses, at a time of changing climactic conditions. It has
previously been shown that viral infection and allergen
exposure in allergen sensitised asthmatics are associated
with increased hospital admissions for acute asthma
[11]. The same study demonstrated the protective effect
of inhaled corticosteroids on acute asthma exacerbations
in a paediatric asthma population [11].
In previous research by the study team a random sam-
ple of around 75,000 school age (5–16 years) children
were observed, using a data set from selected general
practices within the General Practice Research Database
(now the Clinical Practice Research Datalink [12]), who
had a documented medical diagnosis of asthma. Age
(within 2 years) and sex matched controls from the same
practice were also taken [13]. The investigation con-
firmed the increase in unscheduled medical contacts in
children with asthma throughout the year with an ap-
proximate doubling in medical contacts compared to
non-asthmatic children. Regression analysis showed that
children with asthma were approximately twice as likely
as controls to have unscheduled medical contact and
were more likely to see their doctor around the return
to school. If asthmatic children were at a constant in-
creased risk of medical contacts throughout the year
Figure 1 would show a random scatter of the residuals
in England. However, around the return to school thereFigure 1 Mean residuals for excess medical contacts for children with
from left to right, the 1st September, 1st January and 1st April with LOESSwas a pronounced positive increase in the value of resid-
uals (a similar pattern was observed for Scotland). This
indicates that at this time there was a greater than
expected increase in the number of contacts by children
with asthma compared to controls.
It could therefore be argued that July and August are a
good time to have asthma; the pollen season is almost
over, school age children are not at school and so have
less opportunity to pick up any viral infections that are
going through the population.
In the same study we also observed a drop in prescrip-
tions for inhaled steroids in August immediately preced-
ing the return back to school with 25% fewer
prescriptions in August compared to July and September
[13] (see Figure 2). This drop in prescriptions precedes
the viral challenge of a return back to school. We further
showed that patients who received a prescription for in-
haled corticosteroid had 0.14 fewer contacts per patient
(95% CI 0.12 to 0.16, P < 0.001, England; 95% CI 0.10 to
0.18, P < 0.001, Scotland) than those who did not receive
an August prescription.
To interpret the figure of 0.14: hypothetically imagine
a cohort of 200 children with asthma on inhaled cortico-
steroids, where 100 receive an August prescription and
100 do not. If the 100 patients with a prescription make
a total of 50 unscheduled medical visits (0.5 mean visits/
patient) then 64 unscheduled medical contacts would be
made by those not receiving a prescription (0.64 mean
visits/patient; difference 0.14). Hence, per 100 children
with asthma on inhaled corticosteroid not receiving a
prescription in August there is an excess of 14 unsched-
uled medical contacts. Unplanned medical contacts cost
the NHS: £36 for a contact in surgery; £121 for a GP
home visit [14]; £59 to £142 for an emergency depart-
ment contact if not admitted and £74 to £249 if admit-
ted; £385 for a non-elective short stay for asthma
without complications [15].asthma for over controls in England. The vertical lines represent,
smoothing curve that enables trends to be seen [13].
Figure 2 Average daily prescriptions by month for England and Scotland.
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reduce their inhaled corticosteroids over the summer
months or run low of other medications, and fail to re-
start them before the return to school, are more at risk
of acute asthma exacerbation.
The PLEASANT trial will be observing the effect of a
brief postal intervention sent to school aged children
(4–16) with asthma. A letter, will be sent by their
General Practitioner (GP) at the start of the school
summer holidays, encouraging continuation with their
prescribed asthma medication before the start of the
new school year. We will assess the impact this has
on subsequent unscheduled NHS contacts and reduc-
tion in exacerbation of asthma.
Methods/Design
Study design
PLEASANT is a cluster randomised trial. A total of
140 General Practices (GPs) will be recruited into the
trial; 70 GPs randomised to the intervention and 70
control practices of “usual care” (Figure 3). An aver-
age practice is expected to have approximately 100
children eligible hence data will be collected on over
14000 children over a 12 month period. This is a
non-commercial, portfolio study adopted by the Pri-
mary Care Research Network.
Primary research objective
The aim of the trial is to assess if a brief postal inter-
vention reduces the number of unscheduled medical
contacts after the return to school. The primary
objective of the study is to assess whether the inter-
vention reduces the September peak in total medical
contacts and subsequent exacerbations in asthma.
Primary outcome measure
1. The proportion of patients aged between 5–16
who have an unscheduled medical contact in
SeptemberSecondary outcome measures
1. The proportion of patients who have an
unscheduled medical contact in the period
September-December
2. The total number of medical contacts (scheduled
and unscheduled) per patient in September and in
the period September-December
3. The time to first unscheduled medical contact in
September and in the period September-December
4. The proportion of patients who have a medical
contact (either scheduled or unscheduled) in
September and in the period September-December
5. The total number of medical contacts (either
scheduled and unscheduled) per patient in
September and in the period September-December
6. The time to first medical contact in September and
in the period September-December
7. The proportion of patients who have an
unscheduled medical contact in September and in
the period September-December associated with a
respiratory diagnosis
8. The number of unscheduled medical contacts per
patient in September and in the period September-
December associated with a respiratory diagnosis
9. The time to first unscheduled medical contact
associated with a respiratory diagnosis in September
and in the period September-December
10. The number of prescriptions per patient in the
month of August
11. The number of prescriptions in the 12 months
following the intervention
12. The proportion of patients who have a scheduled
medical contact (for example asthma review) in August
13. The proportion of patients who have a scheduled
medical contact (for example asthma review) in the
12 months following the intervention.
The above analyses will be undertaken on patients aged
5 years - 16 years, since asthma is difficult to diagnose in
Figure 3 Trial summary.
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analysed separately to these (see the statistical analysis
section for more details).Setting and site recruitment
The trial will be conducted within primary care with
GPs that are currently part of Clinical Practice Re-
search Datalink (CPRD). Invitation letters will be sent
out, via CPRD, to all current active GP CPRD sites
within England and Wales. 140 sites are expected to
be recruited within 6-month (1st January 2013 to
30th June 2013) based on CPRD’s previous experience
of recruiting GPs to research trials [12].
Support will also be accessed from the Primary
Care Research Network (PCRN) to advertise the trial.
Interested practices will be forwarded further infor-
mation regarding the practicalities of delivering on
the study including sign up to CPRD, if they are notalready members, as this is a requirement for
participation.Randomisation
The randomisation will be stratified by size of prac-
tice to ensure that there is an equal sample size – in
terms of number of school age asthmatic children –
in each arm of the trial. The allocation ratio will be
1:1. The randomisation list will be generated using
the Stata statistical software. Randomisation will be
done centrally: upon confirming their participation,
practices will be randomised to one of the two arms;
intervention vs usual care. Randomisation will be
undertaken by a statistician within the University of
Sheffield’s Clinical Trials Research Unit (CTRU), in
line with the randomisation plan.
GPs randomised to intervention will be asked to
send the postal intervention to eligible patients; GPs
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and will not be required to do anything further.
Site compliance
A member of the study team will be responsible for
site set up and maintaining on-going contact with the
GP setting. Site set up will be done either via tele-
phone or video conferencing. For those sites that pre-
fer a face-to-face contact the study team will either
do the visit (if within a reasonable distance) or liaise
with the appropriate local PCRN to do the visit on
their behalf.
An electronic GP study information pack will be sent
out to all sites with a flow chart to show progress
through the trial period, timing of intervention, informa-
tion required from sites and subsequent NHS service
support cost payments.
Withdrawal
Practices are free to withdraw from the trial at any time.
This will be documented on a site withdrawal form. Any
data already collected during the course of the trial up
to the point of withdrawal will be used in the final ana-
lysis. With permission from the site data will be retained
from the practice as supplied by CPRD.
Target population for intervention
The population targeted for the intervention will be
school aged asthmatic children (aged between 4 and 16
years) registered with a GP.
Inclusion criteria
Children aged between 4 and 16 years of age as of 1st
September 2013 with a coded diagnosis of asthma who
have been prescribed asthma medication in the previous
12 months.
Exclusion criteria
Children aged 4 and under and over 16 years of age as
of 1st September 2013, children who are not considered
appropriate for this intervention by their GP, and chil-
dren who are not receiving asthma medication and have
no co-existing neoplastic disease.
The CPRD will identify eligible participants based on
pre-agreed diagnostic codes for asthma and the inclu-
sion/exclusion criteria. CPRD will send the list of eligible
participants for the GPs to check and confirm. The
study team will receive anonymised observation data
thus informed consent will not be required.
Trial intervention
A brief postal intervention (letter) has been designed
specifically for the PLEASANT trial, developed with
input from the study team, which includes a GP,Psychologist and Consultant Respiratory Paediatrician as
well as the trial steering committee. It has also been
discussed in detail, and reviewed, at two patient and
public events that included school aged children with
asthma and their parents.
The letter highlights the potential risks associated with
stopping, or running low on, asthma medication during
the school summer holidays and the effect this may have
on exacerbation of asthma when returning to school. It
encourages maintaining, or restarting if stopped, medi-
cation and to contact the GP or practice nurse if a pre-
scription is required or clarification is needed on the
dose. A copy of the intervention/letter is available upon
request and will be published on the PLEASANT web-
site from October 2013.
The intervention will be sent, from the GP, to the par-
ents/carers of children with asthma at the beginning of
the summer school holidays (week commencing 29th
July 2013).Data collection
Clinical Practice Research Datalink
The CPRD is a computerised database of anonymised
longitudinal medical records from primary care [18].
The CPRD are able to capture all medical contacts,
from prescription request through to out of hours
contacts, along with the reason for the contact. This
therefore negates the need to request this information
from the GP, reduces practice burden, and ensures
complete data sets.
CPRD will extract data from GP medical records 3
times; baseline (NHS contacts for the previous 12
months) and at 1 month and 12 months post interven-
tion. The study team will not have access to any patient
identifiable data and will receive all data fully
anonymised.Allocation of scheduled versus unscheduled contacts
Every NHS service contact is coded by the GP practice
and captured within the practice database. Using these
codes we will allocate to either scheduled or unsched-
uled contact.
A scheduled contact is defined as any contact that is
part of the planned care for the patient, for example an
asthma review; a medical review; repeat prescription or
immunisation. An unscheduled contact will be any con-
tact not part of the patient’s care plan that is either pa-
tient initiated or as a result of illness.
To ensure the allocation of scheduled and unsched-
uled contacts are robust an adjudication panel,
consisting of 3 GPs, will independently review the pre-
scription and diagnosis codes allocating to either sched-
uled or unscheduled contact.
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Sample size
From previous research in the CPRD practice population
30% of school age asthmatic children had at least one
unscheduled medical contact within the month of
September [13]. We postulate that the intervention may
reduce the number of children who have unscheduled
medical contacts from 30% to 25% (i.e. an absolute re-
duction of 5%). This gives an effect size of 5%. The aver-
age practice size in the CPRD is 8,294. We thus
anticipate circa 100 school-age asthmatic patients per
practice (based on 12% of a practice being school age
children and 11% of school-age children having asthma).
Hence, to detect a difference of 5% with 90% power and
two-sided significance level of 5%, with an intra-class
correlation (ICC) of 0.03 to account for clustering we re-
quire 70 practices per arm. The sample size of 140 prac-
tices would equate to approximately 14,000 school age
asthmatic patients.
Ukoumunne et al. [19] give estimates of ICCs for pa-
tients with respiratory symptoms in symptoms in Gen-
eral Practice. Based on the work of Ukoumunne et al. an
ICC of 0.03 is a conservative estimate. The power of the
study for ICCs of 0.01, 0.02, 0.03, 0.04 and 0.05 is re-
spectively 99.4, 96.0, 90.0, 83.1 and 76.2%.
As a further sensitivity analysis we will investigate the
effect of practices not sending out the letter as planned.
Suppose 10 practices failed to send out the letter, these
would still be included in the primary analysis under the
intent-to-treat principle. However, the effect that could
be observed would be reduced to 4.3%. Under the sam-
ple assumptions (ICC = 0.03, etc.) the power for the
same sample size is reduced to 79.3%. This is a little
under 80% but it does demonstrate that the study is rea-
sonably robust to at least one deviation in the planned
design.Data analysis
The study periods are defined in three stages. The pri-
mary study period is 1st – 30th September 2013, since
this is the period when the intervention is felt likely to
impact. The extended study period is 1st September -
31st December 2013, since asthma-related appointments
are more frequent in the entire period. The follow-up
period is 12 calendar months from 1st September 2013
to 31st August 2014.
The primary analyses will be by intent-to-treat among
patients aged 5–16 years as of 1st September 2012. The
primary endpoint (the proportion of patients who have
an unscheduled medical contact in September) will be
analysed by logistic regression in which the covariates
will include the individual's age; gender; number of con-
tacts the previous September; the trial arm (interventionor control); and the design/cluster effect of general prac-
tice as a random effect.
The same approach will be used for analyses based on
the extended period. The proportion of patients who
have an unscheduled medical contact, the proportion of
patients who have any medical contact; and the propor-
tion of patients who have an unscheduled medical con-
tact associated with respiratory illness. The number of
unscheduled medical appointments per patient in the
extended period; the total number of medical contacts
(scheduled and unscheduled) per patient in the extended
period; the number of unscheduled medical contacts per
patient associated with a respiratory diagnosis in the ex-
tended period; the number of prescriptions per patient
in the month of August; and the number of prescrip-
tions per patient in the 12 months following the inter-
vention will be analysed in an analogous approach to the
primary endpoint. A random effects negative binomial
model will be fitted, including the same covariates as
above. Further analyses will address the time to first
medical contact (defined as the number of days from the
start of school term (2nd September 2013) to the date of
first appointment, up to and including December 2013,
the time to first medical contact up to and including
December 2013, and the time to first unscheduled med-
ical contact associated with a respiratory diagnosis.
These analyses will be conducted using a random effects
("shared frailty") regression model including the same
covariates as described previously.
Patients aged 4–5 will be analysed separately to those
aged 5–16, since the diagnosis of asthma is more contro-
versial in this age group; it is often not practical to
measure variable airway obstruction below the age of 5
making diagnosis of asthma difficult [16,17]. The impact
of the intervention in patients under 5 will be compared
to that seen in the main analysis to assess whether the
intervention appears to benefit younger children. Add-
itional exploratory analyses will investigate whether the
impact of the intervention is related to age or other
characteristics of the patient.
A detailed description of the statistical analysis of effi-
cacy and safety outcomes will be written in the trial Stat-
istical Analysis Plan which will be finalised prior to
receiving post-intervention data from CPRD. The trial
will be reported using the principles highlighted in the
CONSORT statement for reporting cluster RCTs [20].Economic evaluation
An exploratory economic evaluation will be undertaken
to compare the incremental cost per quality adjusted life
year (QALY) of the intervention versus standard care.
The perspective of the analysis will be that of the NHS
and Personal Social Services. The time horizon will be
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discounting will be applied.
Data on the number and type of medical contacts in
the intervention and control arms will be collected
through the CPRD, and combined with PSSRU unit
costs [14] and Department of Health reference costs
[15] to assess the cost of medical contacts in each arm.
Unscheduled contacts in September will be included to
capture the impact of any reduction in asthma exacerba-
tions. Scheduled contacts in the year following interven-
tion will be included to capture any change in health
care resource use in response to the letter. These will be
reported separately in addition to reporting the overall
costs of medical contacts for each arm. Prescription
costs will be assessed for the year following intervention
by combining data on the number of prescriptions with
unit cost data from the British National Formulary
(BNF). The costs for prescriptions and medical contacts
will be combined to give overall costs in the control
arm. In the intervention arm the overall cost will also in-
clude the cost of sending out the intervention, which
will be based on the national primary care costing tem-
plate from the UK National Institute for Health Research
(NIHR) Primary Care Research Network (PCRN) [21].
An existing systematic review [22] has found evidence
showing that asthma exacerbations have a significant im-
pact on quality of life [23]. This review will be updated
to identify any more recent publications, and literature
evidence will be used to determine the health-related
quality of life decrement associated with an asthma
exacerbation that results in an unscheduled medical
contact. From this the QALY gain of preventing asthma
exacerbations with be estimated. We will assume that
the intervention has no effect on survival and therefore
any QALY gain will be wholly driven by improvements
in quality of life achieved by preventing asthma
exacerbations.
This evidence will inform a simple decision-analytic
model to estimate the mean costs and QALYs for the
intervention and control groups. Univariate sensitivity
analyses and probabilistic sensitivity analyses will be
used to examine the uncertainty in the model, with
results displayed using cost-effectiveness planes and
cost-effectiveness acceptability curves [24].Safety assessments & reporting procedures
The trial intervention is aiming to optimise usual asthma
care and improve adherence to medications already pre-
scribed by the GP, thus reducing potential exacerbation
of asthma following return to school in September.
Therefore involvement in the trial should not result in
any adverse or serious adverse events as a result of
participation.Any asthma complications relating to the health of the
child would be picked up by their GP or out of hours
service and managed as per usual care. These unsched-
uled/emergency contacts with NHS services will be
picked up as part of the routine outcome data and de-
scribed within the final trial report. Therefore there are
no formal reporting procedures, for adverse events or
serious adverse events, in place.
Practices randomised to the intervention will be pro-
vided with a short reporting template to inform the
study team of any incidents they feel are related to the
conduct of the trial.Trial governance
Two committees are being established to govern the
conduct of the study:
1. Trial Management Group (TMG)
2. Trial Steering Committee (TSC)
All committees are governed by Sheffield CTRU stand-
ard operating procedures. The TMG consists of the
Principal Investigator, co-investigators and key staff
within the CTRU. The role of the TMG is to implement
all parts of the trial.
The TSC consists of the Principal Investigator, key
staff within the CTRU (as non-voting members), an in-
dependent chair and two independent members (includ-
ing a statistician) and 2 lay members. The roles of the
TSC are to provide supervision of the protocol and stat-
istical analysis plan, and to provide advice on and moni-
tor progress of the trial. A Data Monitoring and Ethics
Committee (DMEC) will not be required for this trial so
the TSC will also consider any issues related to patient
safety.Monitoring arrangements
Once all research governance approvals are in place the
study team will contact each GP site for a study set up
meeting. This will be before randomisation to check the
site has all the necessary information and staff in place
before starting the study. Following the intervention
there will be a one-off follow-up to ensure the interven-
tion has been delivered within the time specified. No
further contact will be required from the practices.Ethical considerations
The study has been approved by the South Yorkshire
Research Ethics Committee on 25th October 2012 refer-
ence: 12/YH/0478 and will be conducted in accordance
with the Research Governance Framework for Health
and Social Care 2005 [25].
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The PLEASANT trial research team is committed to the
principles of patient and public involvement (PPI) [26]
and have ensured that best practice on PPI has been
followed [27]. Children with asthma and their parents
have been involved in the design of the trial and will be
involved throughout the conduct of the study.
PPI in the design of the trial
During the design of the trial, a PPI consultation event
was held in January 2011 with a group of children with
asthma and their parents. This event was used to investi-
gate whether the hypothesis underlying the trial was sup-
ported by children with asthma and their parents, to give
an opportunity for the children and parents to discuss the
wording of the intervention (the GP letter) and to give
their views on to whom the letter should be addressed (i.e.
should it be addressed to the child or to their parent/
guardian). This initial PPI consultation event was written
up as a University of Sheffield report [28].
PPI throughout the trial
PPI during the conduct of the study will have two com-
ponents: (1) two PPI consultation events, the first held
in September 2012 (written up as a University of
Sheffield report [29]) and one planned for December
2014/January 2015, involving up to 6 children and their
parents/guardians; (2) parents of children with asthma
will be invited to become members of the TSC (of which
three accepted), which will meet twice in the first year
and once in the final year of the study.
For attending the consultation events, each child will
be provided with a £20 gift voucher and their parents
will be able to claim for their expenses such as travel.
Parents of children with asthma on the TSC will be
paid for their time at a rate of £50 per meeting, and will
receive travel expenses. The study’s PPI lead will offer to
meet with the parent members of the TSC before or
after each meeting to discuss the agenda items and any
issues of concern, and will act as a mentor for them.
Finance and indemnity
The trial has been financed by the NIHR Health Tech-
nology Assessment (HTA) Programme. This is an NHS
sponsored study. If there is negligent harm during the
clinical trial when the NHS body owes a duty of care to
the person harmed, NHS indemnity will cover NHS staff
and those conducting the trial. The trial will be
conducted in accordance with the Medicines for Human
Use (Clinical Trials) Regulations (SI2004/1031) [30].
The University of Sheffield has in place insurance
against liabilities for which it may be legally liable and
this cover includes any such liabilities arising out of this
clinical trial.Independent scientific review
The trial has been independently reviewed by the HTA
prior to funding and by the Independent Scientific Advis-
ory Committee (ISAC) for Medicines and Healthcare
products Regulatory Agency (MHRA) database research.
Reporting and dissemination
Results of the trial will be disseminated in peer reviewed
scientific journals and clinical and academic conferences.
A patient and public event will also be held to feedback to
those involved in the development of the study protocol.
Details of the trial will also be made available on the
study website [31]. Summaries of the research will be
updated periodically to inform readers of the on-going
progress.
Discussion
The PLEASANT trial will assess whether a brief postal
intervention from the GP can reduce unscheduled ap-
pointments and exacerbation of asthma in school aged
children associated with the return to school after the
summer holidays. It has the potential to benefit the
health and quality of life of children with asthma while
also improving the effectiveness of NHS services by re-
ducing NHS use in one of the busiest months of the
year.
An exploratory health economic analysis will gauge
any cost saving associated with the intervention and sub-
sequent impacts on quality of life. If results for the inter-
vention are positive it is hoped that this is could be
adopted as part of routine care management of child-
hood asthma in general practice.
GP recruitment began in January 2013 with the inter-
vention due to go out at the beginning of the school
summer holidays in July 2013. Observational data will be
collected from approximately 14000 children with final
data collection in December 2014. The final study report
will be written up by June 2015.
Trial status
The trial is currently open and undergoing GP site
recruitment.
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